Tap­ping a biotech boom, Chi­na gene edit­ing CRO Bio­cy­to­gen bags $65M round for glob­al ex­pan­sion

Mon­ey is flow­ing in and out of Chi­na, and it’s touch­ing every part of the ecosys­tem. To­day, a Chi­nese CRO spe­cial­iz­ing in an­i­mal mod­els for gene edit­ing and tar­get­ing spread the word that it has reaped a $65 mil­lion Se­ries C round led by do­mes­tic in­vestors.

Bio­cy­to­gen says the pro­ceeds will go to­ward open­ing up mar­kets both in Chi­na and over­seas, prod­uct R&D, fa­cil­i­ty con­struc­tion and tal­ent re­cruit­ment. CMB In­ter­na­tion­al Cap­i­tal Cor­po­ra­tion, the fi­nan­cial arm of Chi­na Mer­chants Bank, led the round, with sup­port from ex­ist­ing in­vestors like SDIC Ven­ture Cap­i­tal Man­age­ment (Se­ries B lead), 3E Bioven­tures, Cowin Cap­i­tal and Oriza Hold­ings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER